Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

Organon and Co355 enrolled

Overview

A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

355

Conditions

Androgenetic Alopecia

Interventions

MK0906, finasteride / Duration of Treatment : 48 WeeksDRUG

Comparator : placebo (unspecified) / Duration of Treatment : 48 WeeksDRUG

Eligibility

Sex: MALEMin age: 40 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria : * Men 40 to 60 years of age, and in good general physical and mental health, with androgenetic alopecia Exclusion Criteria : * History of previous bladder surgery, acute urinary retention, urethral strictures, repeated urethral catheterizations, repeated urinary tract infections, or active urinary tract infections * History of treatment with finasteride (PROSCAR or PROPECIA) or hypersensitivity to any component of finasteride.

Outcomes

Primary Outcomes

Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment

Secondary Outcomes

Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.